Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia

INTRODUCTION: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. METHODS: Newly diagnosed RUNX1-mutated AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Nachmias, Boaz, Krichevsky, Svetlana, Filon, Dvora, Even-Or, Ehud, Gatt, Moshe E., Saban, Revital, Avni, Batia, Grisariu, Sigal, Aumann, Shlomzion, Vainstein, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808772/
https://www.ncbi.nlm.nih.gov/pubmed/35933982
http://dx.doi.org/10.1159/000526353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808772/
https://www.ncbi.nlm.nih.gov/pubmed/35933982
http://dx.doi.org/10.1159/000526353

Ejemplares similares